"Quinazolines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
Descriptor ID |
D011799
|
MeSH Number(s) |
D03.633.100.786
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Quinazolines".
Below are MeSH descriptors whose meaning is more specific than "Quinazolines".
This graph shows the total number of publications written about "Quinazolines" by people in this website by year, and whether "Quinazolines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 0 | 1 |
1997 | 1 | 0 | 1 |
1998 | 1 | 1 | 2 |
2000 | 0 | 1 | 1 |
2001 | 1 | 1 | 2 |
2002 | 1 | 3 | 4 |
2003 | 6 | 1 | 7 |
2004 | 10 | 7 | 17 |
2005 | 7 | 6 | 13 |
2006 | 9 | 11 | 20 |
2007 | 24 | 13 | 37 |
2008 | 15 | 19 | 34 |
2009 | 14 | 10 | 24 |
2010 | 22 | 8 | 30 |
2011 | 25 | 18 | 43 |
2012 | 12 | 18 | 30 |
2013 | 14 | 25 | 39 |
2014 | 14 | 14 | 28 |
2015 | 13 | 20 | 33 |
2016 | 5 | 8 | 13 |
2017 | 7 | 7 | 14 |
2018 | 2 | 6 | 8 |
2019 | 8 | 1 | 9 |
2020 | 1 | 4 | 5 |
2021 | 8 | 6 | 14 |
2022 | 1 | 7 | 8 |
2023 | 0 | 4 | 4 |
2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Quinazolines" by people in Profiles.
-
Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients. J Pediatric Infect Dis Soc. 2024 Feb 28; 13(Supplement_1):S14-S21.
-
Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study. ESMO Open. 2023 Dec; 8(6):101609.
-
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer. N Engl J Med. 2023 Nov 16; 389(20):1851-1861.
-
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. Clin Cancer Res. 2023 08 15; 29(16):3101-3109.
-
Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma. Clin Cancer Res. 2023 04 03; 29(7):1200-1208.
-
Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma. Pediatr Blood Cancer. 2023 Jan; 70(1):e30017.
-
EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma. Neuro Oncol. 2022 10 03; 24(10):1712-1725.
-
Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer. Cancer Res. 2022 08 16; 82(16):2928-2939.
-
SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia. Future Oncol. 2022 Sep; 18(27):2999-3009.
-
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell. 2022 07 11; 40(7):754-767.e6.